A Study of LY2181308 in Patients With Advanced Hepatocellular Carcinoma
NCT00415155
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
WITHDRAWN
Status
60
Enrollment
INDUSTRY
Sponsor class
Stopped
Trial cancelled
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
LY2181308
Sponsor
Eli Lilly and Company